{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:55:42Z","timestamp":1784303742941,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06038-7","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T01:02:12Z","timestamp":1729645332000},"page":"5341-5349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial"],"prefix":"10.1007","volume":"103","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prassede","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Levato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Finizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Autore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"6","key":"6038_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F (2021) Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 11(6):123","journal-title":"Blood Cancer J"},{"issue":"13","key":"6038_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S et al (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16(13):1295\u20131305","journal-title":"Lancet Oncol"},{"issue":"2","key":"6038_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"6","key":"6038_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M et al (2017) Improved outcomes with retinoic acid and Arsenic Trioxide compared with retinoic acid and chemotherapy in Non-high-risk Acute promyelocytic leukemia: final results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 35(6):605\u2013612","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6038_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2023-185121","volume":"142","author":"L Guarnera","year":"2023","unstructured":"Guarnera L, Lehmann S, D\u00f6hner K, D\u00f6hner H, Platzbecker U, Russell NH et al (2023) Long-term outcome of 1296 patients with newly diagnosed with APL: a Harmony Alliance Study. Blood 142(Supplement 1):727","journal-title":"Blood"},{"issue":"5","key":"6038_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 72(5):409\u2013436","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"6038_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s11764-019-00793-7","volume":"13","author":"I Ramsey","year":"2019","unstructured":"Ramsey I, de Rooij BH, Mols F, Corsini N, Horevoorts NJE, Eckert M et al (2019) Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out. J Cancer Surviv 13(6):829\u2013839","journal-title":"J Cancer Surviv"},{"issue":"5","key":"6038_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bjh.18139","volume":"197","author":"A Ekels","year":"2022","unstructured":"Ekels A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, Issa DE, Koster A et al (2022) Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-hodgkin lymphoma survivors: a longitudinal PROFILES registry study. Br J Haematol 197(5):590\u2013601","journal-title":"Br J Haematol"},{"issue":"10","key":"6038_CR9","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1158\/1055-9965.EPI-11-0673","volume":"20","author":"JP Harrop","year":"2011","unstructured":"Harrop JP, Dean JA, Paskett ED (2011) Cancer survivorship research: a review of the literature and summary of current NCI-designated cancer center projects. Cancer Epidemiol Biomarkers Prev 20(10):2042\u20132047","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"6038_CR10","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s11136-018-1979-0","volume":"27","author":"BH de Rooij","year":"2018","unstructured":"de Rooij BH, Ezendam NPM, Mols F, Vissers PAJ, Thong MSY, Vlooswijk CCP et al (2018) Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: the population-based PROFILES registry. Qual Life Res 27(12):3313\u20133324","journal-title":"Qual Life Res"},{"issue":"30","key":"6038_CR11","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.2014.55.3453","volume":"32","author":"F Efficace","year":"2014","unstructured":"Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Bona ED et al (2014) Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in patients with Acute promyelocytic leukemia: Health-Related Quality-of-life outcomes. J Clin Oncol 32(30):3406\u20133412","journal-title":"J Clin Oncol"},{"issue":"21","key":"6038_CR12","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1182\/bloodadvances.2021004649","volume":"5","author":"F Efficace","year":"2021","unstructured":"Efficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P et al (2021) Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. Blood Adv 5(21):4370\u20134379","journal-title":"Blood Adv"},{"issue":"7","key":"6038_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/17474086.2021.1943352","volume":"14","author":"F Efficace","year":"2021","unstructured":"Efficace F, Cannella L, Breccia M, Olivieri J, Platzbecker U, Vignetti M (2021) Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. Expert Rev Hematol 14(7):645\u2013654","journal-title":"Expert Rev Hematol"},{"key":"6038_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"6038_CR15","unstructured":"Fayers P, Aaronson N, Bjordal K et al (2001) EORTC QLQ-C30 Scoring Manual. 3rd Edition, Brussels, Belgium, EORTC Publications"},{"issue":"26","key":"6038_CR16","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","volume":"131","author":"MS Topp","year":"2018","unstructured":"Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A et al (2018) Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood 131(26):2906\u20132914","journal-title":"Blood"},{"issue":"Supplement 1","key":"6038_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1182\/blood-2022-166544","volume":"140","author":"F Efficace","year":"2022","unstructured":"Efficace F, Huls GA, Kicinski M, Van Der Velden WJ, Noppeney R, Chantepie S et al (2022) 10-Day decitabine Versus Intensive Chemotherapy Followed by Transplantation in Fit AML patients aged\u2009\u2265\u200960 years: Health-Related Quality of Life outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG. Blood 140(Supplement 1):1281\u20131283","journal-title":"Blood"},{"issue":"6","key":"6038_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 30(6):473\u2013483","journal-title":"Med Care"},{"issue":"4 Suppl","key":"6038_CR19","first-page":"AS264","volume":"33","author":"JE Ware Jr","year":"1995","unstructured":"Ware JE Jr., Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A (1995) Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical outcomes Study. Med Care 33(4 Suppl):AS264\u2013AS279","journal-title":"Med Care"},{"issue":"2","key":"6038_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2011.40.6249","volume":"31","author":"SK Smith","year":"2013","unstructured":"Smith SK, Mayer DK, Zimmerman S, Williams CS, Benecha H, Ganz PA et al (2013) Quality of life among long-term survivors of non-hodgkin lymphoma: a follow-up study. J Clin Oncol 31(2):272\u2013279","journal-title":"J Clin Oncol"},{"issue":"17","key":"6038_CR21","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554\u20134560","journal-title":"Blood"},{"issue":"2","key":"6038_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13(2):63\u201374","journal-title":"J Pain Symptom Manage"},{"issue":"3 Suppl 2","key":"6038_CR23","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13\u201319","journal-title":"Semin Hematol"},{"issue":"1","key":"6038_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89\u201396","journal-title":"J Clin Oncol"},{"issue":"1","key":"6038_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/009286150303700105","volume":"37","author":"J Sloan","year":"2003","unstructured":"Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inform J 37(1):23\u201331","journal-title":"Drug Inform J"},{"issue":"10","key":"6038_CR26","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3899\/jrheum.090193","volume":"36","author":"KJ Colangelo","year":"2009","unstructured":"Colangelo KJ, Pope JE, Peschken C (2009) The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 36(10):2231\u20132237","journal-title":"J Rheumatol"},{"issue":"3","key":"6038_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3899\/jrheum.090375","volume":"37","author":"S Sekhon","year":"2010","unstructured":"Sekhon S, Pope J, Baron M (2010) The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. J Rheumatol 37(3):591\u2013598","journal-title":"J Rheumatol"},{"issue":"6","key":"6038_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","volume":"24","author":"D Cella","year":"2002","unstructured":"Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24(6):547\u2013561","journal-title":"J Pain Symptom Manage"},{"key":"6038_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","volume":"118","author":"JM Giesinger","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F et al (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1\u20138","journal-title":"J Clin Epidemiol"},{"key":"6038_CR30","doi-asserted-by":"crossref","unstructured":"Yin XJ, Wang R, Shen HS, Jin J, Zhu HH (2023) At what point are long-term (>\u20095 years) survivors of APL Safe? A study from the SEER database. Cancers (Basel). 15(3)","DOI":"10.3390\/cancers15030575"},{"issue":"11","key":"6038_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1182\/blood-2016-02-699439","volume":"128","author":"H Zhu","year":"2016","unstructured":"Zhu H, Hu J, Chen L, Zhou W, Li X, Wang L et al (2016) The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood 128(11):1525\u20131528","journal-title":"Blood"},{"issue":"2","key":"6038_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bmjspcare-2020-002281","volume":"12","author":"K Sommer","year":"2022","unstructured":"Sommer K, Vignetti M, Cottone F, Breccia M, Annibali O, Luppi M et al (2022) Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. BMJ Support Palliat Care 12(2):182\u2013186","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"6038_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2012.064907","volume":"98","author":"S Oerlemans","year":"2013","unstructured":"Oerlemans S, Mols F, Issa DE, Pruijt JH, Peters WG, Lybeert M et al (2013) A high level of fatigue among long-term survivors of Non-hodgkin\u2019s lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica 98(3):479\u2013486","journal-title":"Haematologica"},{"issue":"2","key":"6038_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/10428194.2022.2142050","volume":"64","author":"CE Kiserud","year":"2023","unstructured":"Kiserud CE, Lockmer S, Baerug I, Dahl AA, Kimby E, \u00d8stenstad B (2023) Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma - a comparison with normative data. Leuk Lymphoma 64(2):349\u2013355","journal-title":"Leuk Lymphoma"},{"key":"6038_CR35","doi-asserted-by":"publisher","unstructured":"Sparano F, Voso MT, Venditti A, Giesinger JM, Baldi T, Breccia M et al (2024) Financial toxicity and health-related quality of life in long-term survivors of acute promyelocytic leukaemia. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/spcare-2024-004924","DOI":"10.1136\/spcare-2024-004924"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06038-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06038-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06038-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:11:27Z","timestamp":1735866687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06038-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6038"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06038-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and each center received approval from their ethic committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"After having received approval from the local Ethics Committees, the investigators of each center invited eligible patients to participate. Patients who consented to participate were included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Fabio Efficace had a consultancy or advisory role for AbbVie, Incyte,\u00a0Syros, Novartis and JAZZ Pharmaceuticals and Research support (institution) from Daiichi Sankyo, all outside the submitted work.Uwe Platzbecker: honoraria: Abbvie, Curis, Janssen.Marco Vignetti reports honoraria from AbbVie, Amgen, AstraZeneca, Dephaforum Srl., Incyte Corporation, and Novartis; and personal fees from Amgen outside the submitted work.Massimo Breccia reports fees for expert witness testimony from Incyte Corporation, Novartis Pharma, and Pfizer, Inc., outside the submitted work; and he is also Editor-In-Chief of this journal.All other co\u2010authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}